NCT05222945View on ClinicalTrials.gov

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

NANot yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

October 31, 2025

Conditions
HIV-1-infection
Interventions
OTHER

Biopsies and bloood samplings

blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample

Trial Locations (6)

Unknown

Antoine-Beclere Hospita, Clamart

Bicetre Hospital, Le Kremlin-Bicêtre

Hotel Dieu Hospital, Paris

Necker Hospital, Paris

Pitie Salpetriere Hospital, Paris

Saint Antoine Hospital, Paris

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT05222945 - A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide | Biotech Hunter | Biotech Hunter